Cardiovascular Effects of GLP-1 Receptor Activation

NCT03101930 on ClinicalTrials.gov · last registry update 2022-10-18

An unusually large phase 4: 329 participants, more than double the 75 typical for the stage. The sponsor logged completion for 24 June 2021. Primary outcome, as filed: Change in Flow-mediated Dilation. liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Vanderbilt University Medical Center
Sponsor type: Other
Enrollment: 329
Started: 2017-05-01
Primary completion: 2021-06-24 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Flow-mediated Dilation

Conditions studied

Obesity · PreDiabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.